retatrutide type 2 diabetes trial 2024 phase 2 results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, retatrutide type 2 diabetes phase

Patient Cost Sharing Library The Complex Web Behind Low Persistence Low persistence in GLP-1 therapy is rarely the result of a single factor

Recharge nutrient levels, uplift your wellness, get hydrated and secure optimal health

Here are some ways to boost your protein and fiber intake: Start your day with a protein-packed breakfast like eggs or Greek yogurt

But GLP-1 treatment for obesity is far less clear

While GLP-1 medication do not directly increase energy in the traditional sense (like a stimulant would), it helps by regulating blood sugar, reducing body weight, and improving metabolic health, all of which can lead to more consistent and sustainable energy levels

Mussel-inspired polydopamine: a biocompatible and ultrastable coating for nanoparticles in vivo